Beam Therapeutics Inc. Equity-NMS: BEAM

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$63.43

1Y :

-40.85%

5Y :

159.18%

What is the share price of Beam Therapeutics Inc. today?

Beam Therapeutics Inc. (BEAM) share price as of August 8, 2022, is $63.69. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Beam Therapeutics Inc.?

Yes, Indian Investors can invest in the Beam Therapeutics Inc. (BEAM) Share by opening an international trading account with Angel One.

How can I purchase Beam Therapeutics Inc. shares in India?

Purchasing Beam Therapeutics Inc. (BEAM) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Beam Therapeutics Inc. (BEAM) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Beam Therapeutics Inc.?

Yes, you can purchase fractional shares of Beam Therapeutics Inc. (BEAM) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Beam Therapeutics Inc.?

The market capitalization of Beam Therapeutics Inc. on August 9, 2022, is $0.

In which sector Beam Therapeutics Inc. belongs?

Beam Therapeutics Inc. operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Beam Therapeutics Inc. stocks?

In order to invest in Beam Therapeutics Inc. (BEAM) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Beam Therapeutics Inc. is a biotechnology company. The Company is focused on developing precision genetic medicines based on its base editing technology to provide life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company’s base editing technology of therapeutic applications pursue a suite of both clinically validated and delivery modalities, depending on tissue type, which includes electroporation for delivery to blood cells and immune cells ex vivo; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future, and adeno-associated viral vectors (AAV), for in vivo viral delivery to the eye and potentially other organs. The Company has four development candidates, which include BEAM-101, BEAM-102, BEAM-201 and BEAM-301.